Nov 4, 2011
Avanir Pharmaceuticals has enrolled first patient in Prime study of AVP-923 to treat central neuropathic pain in patients with multiple sclerosis (MS).
The double-blind, multicenter, placebo-controlled, randomized study is designed to assess the safety, tolerability, and efficacy of AVP-923.
The primary efficacy endpoint will be measured based on the Numeric Pain Rating Scale as recorded in patient diaries.
Secondary assessments include measures of fatigue, impact of MS on daily life, sleep quality, cognition and depression.
Avanir research and development senior vice president Joao Siffert said in addition, they look forward to explore the potential of AVP-923 across a broad range of other CNS disorders.
Source: PBR clinical Trials
..
===========================================================
Remain CURRENT with Multiple Sclerosis news and information
Providing You with MS Views and News, is what we do
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
On the Fourth Wednesday of Each Month
Visit: StuMSradio – With Deanna and Stu
CALL-IN To listen, speak with us or speak with a guest
* Call (347) 215-9265 *
or click: Multiple Sclerosis-UnPlugged to listen online
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Help us to educate $ DONATE NOW PLEASE $
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
…………………………
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews